Reexcision rates after partial mastectomy vary greatly

Share this article:
Reexcision rates after partial mastectomy vary greatly
Reexcision rates after partial mastectomy vary greatly

Nearly one-fourth of women who undergo a partial mastectomy have a second surgery to remove additional tissue, and there is substantial surgeon and institutional variation in the rate of reexcisions that cannot be explained by patients' clinical characteristics.

Investigators reached this conclusion after conducting an observational study of breast surgery performed between 2003 and 2008 at four medical institutions (JAMA. 2012;307[5]:467-475). Of 2,206 women (mean age 62 years) with 2,220 newly identified invasive breast cancers who underwent a partial mastectomy, 509 of them (22.9%) had additional surgery. Most patients (454, or 89.2%) had one reexcision, 48 women (9.4%) had two reexcisions, and seven women (1.4%) had three reexcisions.Of the full group of women, 190 (8.5%) eventually had a total mastectomy.

Failure to achieve appropriate surgical margins (the rim of normal tissue around the cancerous tissue) after initial partial mastectomy results in the need for more surgery. Reexcision rates for margin status after the first operation were as follows:

  • 85.9% for initial positive margins
  • 47.9% for margins of less than 1.0 mm
  • 20.2% for margins of 1.0 to 1.9 mm
  • 6.3% for margins of 2.0 to 2.9 mm.

Reexcision rates varied widely among surgeons and institutions for patients with negative surgical margins. The great variation in reexcision rates could not be explained by a patient's medical or treatment history.

As the investigators point out, partial mastectomy is the most commonly performed procedure for invasive breast cancer, and cancer recurrence as well as the patient's overall survival could possibly be affected by differences in initial surgical care.

“The wide level of unexplained clinical variation itself represents a potential barrier to high-quality and cost-effective care of patients with breast cancer,” cautioned study leader Laurence E. McCahill, MD, director of surgical oncology at The Lacks Cancer Center in Grand Rapids, Michigan, in a statement describing his group's findings. 

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.

Triple therapy revs up immune system against a common brain tumor

A triple therapy for glioblastoma, consisting of two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report.

Prostate Cancer Prevention Trial identifies men most likely to undergo biopsy

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all trial steps are most likely to undergo a biopsy at the end of the trial, according to recent research.